Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GLSI 
Greenwich Lifesciences Inc (GLSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: GLSI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $42
1 Year Target Price $42
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.66% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 155.66M USD | Price to earnings Ratio - | 1Y Target Price 42 |
Price to earnings Ratio - | 1Y Target Price 42 | ||
Volume (30-day avg) 1 | Beta 3.16 | 52 Weeks Range 8.06 - 15.50 | Updated Date 09/12/2025 |
52 Weeks Range 8.06 - 15.50 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.37 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -219.03% | Return on Equity (TTM) -491.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 152123526 | Price to Sales(TTM) - |
Enterprise Value 152123526 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -21.23 | Shares Outstanding 13630300 | Shares Floating 6374462 |
Shares Outstanding 13630300 | Shares Floating 6374462 | ||
Percent Insiders 51.3 | Percent Institutions 10.45 |
Upturn AI SWOT
Greenwich Lifesciences Inc
Company Overview
History and Background
Greenwich Lifesciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of immunotherapy to prevent breast cancer recurrence. Founded in 2006, it primarily focuses on advancing its lead product candidate, GP2, a peptide immunotherapy.
Core Business Areas
- Clinical Development: Greenwich Lifesciences focuses on the clinical development of GP2, conducting clinical trials to evaluate its safety and efficacy in preventing breast cancer recurrence.
Leadership and Structure
The leadership team comprises experienced professionals in the biopharmaceutical industry, with Dr. Snehal Patel as CEO. The organizational structure is relatively lean, reflecting its focus on a single core product.
Top Products and Market Share
Key Offerings
- GP2 Immunotherapy: GP2 is the company's primary product, a peptide immunotherapy designed to prevent breast cancer recurrence. Market share is not yet applicable as the product is still in clinical trials. Competitors include companies developing similar cancer immunotherapies, such as large pharmaceutical companies with broad oncology portfolios, and smaller biotechs with focused immunotherapy platforms.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in oncology and immunotherapy, is highly competitive and rapidly evolving. There is significant demand for effective treatments for cancer prevention and recurrence.
Positioning
Greenwich Lifesciences is positioned as a specialized player focused on breast cancer recurrence prevention using immunotherapy. Its competitive advantage hinges on the success of GP2 in clinical trials and its potential to address an unmet need.
Total Addressable Market (TAM)
The global breast cancer therapeutics market is substantial, estimated in billions of USD. Greenwich Lifesciences is targeting a niche within this market u2013 prevention of recurrence u2013 positioning it to potentially capture a significant portion of this niche upon successful commercialization of GP2.
Upturn SWOT Analysis
Strengths
- Focus on a specific unmet need (breast cancer recurrence prevention)
- Proprietary GP2 immunotherapy technology
- Experienced leadership team
Weaknesses
- Reliance on a single product candidate (GP2)
- Limited financial resources compared to larger pharmaceutical companies
- Clinical trial risks and regulatory uncertainties
Opportunities
- Positive clinical trial results could lead to rapid market adoption
- Partnerships with larger pharmaceutical companies for commercialization
- Expansion into other cancer types or immunotherapy applications
Threats
- Failure of GP2 in clinical trials
- Competition from other breast cancer therapies
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- PFE
- MRK
- BMY
- AZN
Competitive Landscape
Greenwich Lifesciences faces significant competition from larger pharmaceutical companies with established oncology portfolios. Its advantage lies in its focused approach to breast cancer recurrence prevention with GP2.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the advancement of GP2 through clinical trials and any partnerships secured.
Future Projections: Future growth depends heavily on the successful completion of clinical trials and regulatory approval for GP2.
Recent Initiatives: Recent initiatives include ongoing clinical trials for GP2 and efforts to secure funding for further development.
Summary
Greenwich Lifesciences is a high-risk, high-reward company focused on GP2, a breast cancer recurrence prevention immunotherapy. Its success hinges on positive clinical trial results, making it a speculative investment. Its strength is its focus, but its reliance on a single product and limited resources are key risks. The company needs to look out for clinical trial setbacks and competition from larger pharmaceutical firms.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings, Industry Reports, Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Greenwich Lifesciences Inc
Exchange NASDAQ | Headquaters Stafford, TX, United States | ||
IPO Launch date 2020-09-25 | CEO, CFO & Director Mr. Snehal S. Patel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | |
Full time employees 4 | |||
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.